CONMED Corp — Director's Dealing 2020

Nov 13, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED CORP (CNMD)
CIK: 0000816956
Period of Report: 2020-11-11

Reporting Person: KENNEDY JOHN JED (VP GM CET)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-11	Common Stock	M	4880	$51.30	Acquired	10489	Direct
2020-11-11	Common Stock	F	3291	$95.17	Disposed	7198	Direct
2020-11-11	Common Stock	M	4940	$39.87	Acquired	12138	Direct
2020-11-11	Common Stock	S	4564	$94.7872	Disposed	7574	Direct
2020-11-11	Common Stock	S	376	$95.5166	Disposed	7198	Direct
2020-11-11	Common Stock	M	5000	$41.93	Acquired	12198	Direct
2020-11-11	Common Stock	S	5000	$94.7511	Disposed	7198	Direct
2020-11-11	Common Stock	M	5400	$59.96	Acquired	12598	Direct
2020-11-11	Common Stock	S	5400	$94.7602	Disposed	7198	Direct
2020-11-11	Common Stock	M	1900	$78.76	Acquired	9098	Direct
2020-11-11	Common Stock	S	1900	$95.1036	Disposed	7198	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-11	Sars (Stock Appreciation Rights)	$51.30	M	4880	Disposed	2025-02-27	Common Stock (4880)	Direct
2020-11-11	Options To Purchase Common Stock	$39.87	M	4940	Disposed	2026-03-01	Common Stock (4940)	Direct
2020-11-11	Options To Purchase Common Stock	$41.93	M	5000	Disposed	2027-03-01	Common Stock (5000)	Direct
2020-11-11	Options To Purchase Common Stock	$59.96	M	5400	Disposed	2028-03-01	Common Stock (5400)	Direct
2020-11-11	Options To Purchase Common Stock	$78.76	M	1900	Disposed	2029-03-01	Common Stock (1900)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.50 to $95.48. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.51 to $95.52. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.50 to $95.375. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.50 to $95.44. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.87 to $95.375. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.

F6: The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (20%) over a five year period.

F7: The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period

F8: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period